Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 May;27(4):479-485.
doi: 10.1111/den.12405. Epub 2014 Dec 11.

Diagnostic and therapeutic utility of SpyGlass(®) peroral cholangioscopy in intraductal biliary disease: single-center, retrospective, cohort study

Alan H Tieu  1 , Vivek Kumbhari  1 , Neha Jakhete  1 , Frances Onyimba  1 , Yuval Patel  1 , Eun Ji Shin  1 , Zhiping Li  1
Affiliations

Diagnostic and therapeutic utility of SpyGlass(®) peroral cholangioscopy in intraductal biliary disease: single-center, retrospective, cohort study

Alan H Tieu et al. Dig Endosc. 2015 May.

Abstract

Background and aim: SpyGlass® cholangiopancreatoscopy system has shown early success in aiding diagnosis and management of pancreaticobiliary diseases. We aimed to assess the technical success, clinical success, diagnostic yield, therapeutic yield, and safety of the SpyGlass® system at a single institution.

Methods: A retrospective, single-center review of consecutive patients who underwent endoscopic retrograde cholangiopancreatography with SpyGlass® between January 2008 and August 2013 for a variety of indications. Technical success was defined as the procedure being completed as planned. Clinical success was defined as a successful outcome using diagnostic, clinical, laboratory, or imaging evidence.

Results: SpyGlass® cholangioscopy was carried out in 88 patients (49 females, mean age 56.9 ± 15.5 years). Indications were diagnostic in 67 and therapeutic in 21. Overall, technical success was seen in 87.5% and clinical success in 77.3%. Thirty-nine patients with indeterminate biliary stricture had technical and clinical success rates of 92.3% and 74.4%, respectively. In this subgroup, malignancy was ultimately diagnosed in 13 with 12 patients diagnosed by SpyGlass® and confirmed by surgical specimens in 12/12 cases; positive predictive value 100%). In the 23 remaining patients with indeterminate biliary strictures, one was later found to have malignancy (negative predictive value 95.8%) after 1 year of follow up. In the 13 therapeutic cases of stone removal, technical and clinical success was seen in 77.0% for both. Overall, adverse events were seen in 15.9%.

Conclusions: SpyGlass® demonstrated acceptable technical and clinical success rates in both diagnostic and therapeutic procedures. In particular, it allows for an accurate rate of diagnosis of indeterminate biliary strictures.

Keywords: SpyGlass® cholangioscopy; biliary disease; biliary endoscopy; intraductal endoscopy; lithotripsy.

PubMed Disclaimer

References

    1. Fritcher EG, Kipp BR, Halling KC et al. A multivariable model using advanced cytologic methods for the evaluation of indeterminate pancreatobiliary strictures. Gastroenterology 2009; 136: 2180-2186.
    1. Carr-Locke DL. Therapeutic role of ERCP in the management of suspected common bile duct stones. Gastrointest. Endosc. 2002; 56 (6 Suppl): S170-174.
    1. Siddique I, Galati J, Ankoma-Sey V et al. The role of choledochoscopy in the diagnosis and management of biliary tract diseases. Gastrointest. Endosc. 1999; 50: 67-73.
    1. Manta R, Frazzoni M, Conigliaro R et al. SpyGlass single-operator peroral cholangioscopy in the evaluation of indeterminate biliary lesions: A single-center, prospective, cohort study. Surg. Endosc. 2013; 27: 1569-1572.
    1. Williamson JB, Draganov PV. The usefulness of SpyGlass choledochoscopy in the diagnosis and treatment of biliary disorders. Curr. Gastroenterol. Rep. 2012; 14: 534-541.

Publication types

MeSH terms

LinkOut - more resources